Lingling Xie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lingling Xie has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
- Li Jiang
Department of Neurology, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Neurodevelopment and Cognitive Disorders, Children’s Hospital of Chongqing Medical University, Chongqing, China
10 shared publications Linxue Meng
Department of Neurology, Children's Hospital of Chongqing Medical University, Chongqing, PR China; National Clinical Research Center for Child Health and Disorders, Chongqing, PR China; China International Science and Technology Cooperation base of Child Development and Critical Disorders, Chongqing, PR China; Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing, PR China; Chongqing Key Laboratory of Pediatrics, PR China
5 shared publicationsHanyu Luo
3 shared publicationsSiqi Hong
National Clinical Research Center for Child Health and Disorders, Chongqing 400014, China; Department of Neurology, Children's Hospital of Chongqing Medical University, Chongqing 400014, China; Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing 400014, China; Chongqing Key Laboratory of Child Neurodevelopment and Cognitive Disorders, Chongqing 400014, China
3 shared publicationsXiaojie Song
Department of Neurology Children's Hospital of Chongqing Medical University Chongqing China
3 shared publicationsYi Guo
National Clinical Research Center for Child Health and Disorders, Chongqing 400014, China; Department of Neurology, Children's Hospital of Chongqing Medical University, Chongqing 400014, China; Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing 400014, China; Chongqing Key Laboratory of Child Neurodevelopment and Cognitive Disorders, Chongqing 400014, China
3 shared publications
Latest Publications
- 2 June 2026
- Published by Elsevier in Epilepsy Research
- Vol. 226, 107842
Phenotype and genotype of people with epilepsy and GABAA receptor gene variants: Genetic and clinical characterization of six children in China
- 2 June 2026
- Published by Elsevier in Epilepsy Research
- Vol. 226, 107842
Phenotype and genotype of people with epilepsy and GABAA receptor gene variants: Genetic and clinical characterization of six children in China
- 5 April 2026
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 138, 84-92
Adjunctive antiepileptic efficacy and safety study of mTOR inhibitors in children with tuberous sclerosis complex
- 5 April 2026
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 138, 84-92
Adjunctive antiepileptic efficacy and safety study of mTOR inhibitors in children with tuberous sclerosis complex
- 6 December 2025
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 134, 152-164
Comparative analysis of clinical phenotypes and genetic characteristics in MEF2C-associated neurodevelopmental disorders
- 6 December 2025
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 134, 152-164
Comparative analysis of clinical phenotypes and genetic characteristics in MEF2C-associated neurodevelopmental disorders
- Open Access
- 11 November 2025
- Published by JMIR Publications Inc. in JMIR mHealth and uHealth
- Vol. 13, e70085
Effects of a Transtheoretical Model–Based mHealth Intervention on Transition Readiness in Adolescents With Epilepsy: Quasi-Experimental Study
Background: Enhancing self-management and transition readiness in adolescents with epilepsy is essential for successful transition to adult care. The combination of the transtheoretical model (TTM) and mobile health (mHealth) management provides a framework for reducing intervention costs while personalizing care. Objective: This quasi-experimental study evaluates the feasibility of TTM-based mHealth management for improving transition services in adolescents with epilepsy. Methods: A total of 98 adolescent patients with epilepsy aged 12-18 years were recruited. Using a nonrandomized design based on treatment locations, they were allocated into either the intervention group (n=49) or the control group (n=49). The intervention group received a TTM-based mHealth management program, which included phase-specific group sessions led by a multidisciplinary team and conducted via Tencent Meeting every 2 weeks or monthly (biweekly for the precontemplation, contemplation, and preparation, and monthly for the action and maintenance). The sessions involved lectures, discussions, and a mini-program that provided disease management support, motivational strategies, and digital reminders tailored to each stage. The control group received conventional remote extended care, consisting of biweekly group lectures and discussions for all patients and their families via Tencent Meeting, supplemented by regular health education materials delivered through a WeChat group. Telephone follow-ups were conducted at the third and sixth months. The total intervention duration was 6 months for both groups. Outcomes were assessed after 6 months using the self-management stage, Self-Management and Transition to Adulthood with Rx=Treatment questionnaire, and a self-developed program acceptability questionnaire. Results: Postintervention, the intervention group demonstrated significantly better self-management behavior stages compared with controls. At the end of 6 months of intervention, the majority of participants in the intervention group reached the action stage (16/49, 32.65%) and maintenance stage (14/49, 28.57%), whereas most controls remained in precontemplation (12/49, 24.49%) and contemplation stages (13/49, 26.53%). Both groups showed significant improvements from baseline in medication management, health care participation, disease knowledge, doctor-patient communication, and transition readiness total scores at 6-month follow-up (all P<.05). Notably, the intervention group achieved additional incremental benefits versus controls (medication management: 3.81, 95% CI 1.26-6.36; health care engagement: 2.77, 95% CI 0.52-5.02; disease knowledge: 1.30, 95% CI 0.28-2.31; provider communication: 3.42, 95% CI 1.62-5.22; transition readiness: 11.30, 95% CI 5.70-6.89; effect sizes [Cohen d] ranged from 0.527 to 0.864, indicating moderate-to-large clinical effects). The overall satisfaction scores were 4.43 (SD 0.50) for patients and 4.16 (SD 0.82) for health care providers. Conclusions: The TTM-based mHealth management program may effectively improve self-management behavior changes and enhance readiness for transition among adolescents with epilepsy, thereby facilitating a smooth transition to adult health care. The program demonstrated high acceptability, providing a reference for establishing clinical transition service protocols. However, this study was a single-center, quasi-experimental trial with a small sample size and short intervention duration. The findings need to be confirmed by larger-scale randomized controlled trials to verify efficacy.
- 11 November 2025
- Published by JMIR Publications Inc. in JMIR mHealth and uHealth
- Vol. 13, e70085
Open AccessEffects of a Transtheoretical Model–Based mHealth Intervention on Transition Readiness in Adolescents With Epilepsy: Quasi-Experimental Study
Background: Enhancing self-management and transition readiness in adolescents with epilepsy is essential for successful transition to adult care. The combination of the transtheoretical model (TTM) and mobile health (mHealth) management provides a framework for reducing intervention costs while personalizing care. Objective: This quasi-experimental study evaluates the feasibility of TTM-based mHealth management for improving transition services in adolescents with epilepsy. Methods: A total of 98 adolescent patients with epilepsy aged 12-18 years were recruited. Using a nonrandomized design based on treatment locations, they were allocated into either the intervention group (n=49) or the control group (n=49). The intervention group received a TTM-based mHealth management program, which included phase-specific group sessions led by a multidisciplinary team and conducted via Tencent Meeting every 2 weeks or monthly (biweekly for the precontemplation, contemplation, and preparation, and monthly for the action and maintenance). The sessions involved lectures, discussions, and a mini-program that provided disease management support, motivational strategies, and digital reminders tailored to each stage. The control group received conventional remote extended care, consisting of biweekly group lectures and discussions for all patients and their families via Tencent Meeting, supplemented by regular health education materials delivered through a WeChat group. Telephone follow-ups were conducted at the third and sixth months. The total intervention duration was 6 months for both groups. Outcomes were assessed after 6 months using the self-management stage, Self-Management and Transition to Adulthood with Rx=Treatment questionnaire, and a self-developed program acceptability questionnaire. Results: Postintervention, the intervention group demonstrated significantly better self-management behavior stages compared with controls. At the end of 6 months of intervention, the majority of participants in the intervention group reached the action stage (16/49, 32.65%) and maintenance stage (14/49, 28.57%), whereas most controls remained in precontemplation (12/49, 24.49%) and contemplation stages (13/49, 26.53%). Both groups showed significant improvements from baseline in medication management, health care participation, disease knowledge, doctor-patient communication, and transition readiness total scores at 6-month follow-up (all P<.05). Notably, the intervention group achieved additional incremental benefits versus controls (medication management: 3.81, 95% CI 1.26-6.36; health care engagement: 2.77, 95% CI 0.52-5.02; disease knowledge: 1.30, 95% CI 0.28-2.31; provider communication: 3.42, 95% CI 1.62-5.22; transition readiness: 11.30, 95% CI 5.70-6.89; effect sizes [Cohen d] ranged from 0.527 to 0.864, indicating moderate-to-large clinical effects). The overall satisfaction scores were 4.43 (SD 0.50) for patients and 4.16 (SD 0.82) for health care providers. Conclusions: The TTM-based mHealth management program may effectively improve self-management behavior changes and enhance readiness for transition among adolescents with epilepsy, thereby facilitating a smooth transition to adult health care. The program demonstrated high acceptability, providing a reference for establishing clinical transition service protocols. However, this study was a single-center, quasi-experimental trial with a small sample size and short intervention duration. The findings need to be confirmed by larger-scale randomized controlled trials to verify efficacy.
- Open Access
- 26 July 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (15) , 7244
The Activation of the Microglial NLRP3 Inflammasome Is Involved in Tuberous Sclerosis Complex-Related Neuroinflammation
Tuberous sclerosis complex (TSC) is a systemic disease caused by mutations in either the TSC1 (encoding hamartin) or TSC2 (encoding tuberin) gene, with mutations in the TSC2 gene potentially leading to more severe clinical symptoms. Neurological symptoms are a common clinical manifestation of TSC, and neuroinflammation is thought to play an important role. Glial cells are a major source of neuroinflammation, but whether microglia are involved in the activation of the NOD-like receptor protein 3 (NLRP3) inflammasome and the expression of interleukin-1β (IL-1β) in TSC patients remains unclear. We used a transcriptome sequencing dataset for bioinformatics analysis to explore the differences in the expression of microglial inflammasome-associated hub genes. TSC2 knockdown (TSC2 KD) microglia (HMC3 cell line) were generated by lentivirus, and the expression of inflammasome-associated hub genes, microglial activation, and NLRP3 inflammasome activation were verified. In addition, experiments were performed to explore the regulatory effects of rapamycin. Bioinformatics analysis identified a total of eight inflammasome-associated hub genes. By detecting GFP fluorescence, TSC2 mRNA, TSC2 protein expression, and the phosphorylation of the mammalian target of rapamycin (p-mTOR)/mTOR, we confirmed that the TSC2 KD microglia model was successfully established. Compared with the control group, the TSC2 KD group presented higher mRNA levels and fluorescence intensities of microglia AIF1 and CD68, as well as greater reactive oxygen species (ROS) production. Eight inflammasome-associated hub gene mRNA assays revealed that the expression of the NLRP3 and IL1B genes was increased. Compared with the control group, the TSC2 KD group presented increased levels of NLRP3 and Pro-IL-1β proteins in cells and Cleaved-Caspase 1 and Cleaved-IL-1β proteins in the supernatant, suggesting NLRP3 inflammasome activation. Rapamycin intervention alleviated these changes, demonstrating that the TSC2 gene regulation of microglial activation and NLRP3 inflammasome activation are correlated with mTOR phosphorylation. In conclusion, microglia are activated in TSC patients and participate in the NLRP3 inflammasome-associated neuroinflammatory response, and rapamycin treatment can alleviate these changes.
- 26 July 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (15) , 7244
Open AccessThe Activation of the Microglial NLRP3 Inflammasome Is Involved in Tuberous Sclerosis Complex-Related Neuroinflammation
Tuberous sclerosis complex (TSC) is a systemic disease caused by mutations in either the TSC1 (encoding hamartin) or TSC2 (encoding tuberin) gene, with mutations in the TSC2 gene potentially leading to more severe clinical symptoms. Neurological symptoms are a common clinical manifestation of TSC, and neuroinflammation is thought to play an important role. Glial cells are a major source of neuroinflammation, but whether microglia are involved in the activation of the NOD-like receptor protein 3 (NLRP3) inflammasome and the expression of interleukin-1β (IL-1β) in TSC patients remains unclear. We used a transcriptome sequencing dataset for bioinformatics analysis to explore the differences in the expression of microglial inflammasome-associated hub genes. TSC2 knockdown (TSC2 KD) microglia (HMC3 cell line) were generated by lentivirus, and the expression of inflammasome-associated hub genes, microglial activation, and NLRP3 inflammasome activation were verified. In addition, experiments were performed to explore the regulatory effects of rapamycin. Bioinformatics analysis identified a total of eight inflammasome-associated hub genes. By detecting GFP fluorescence, TSC2 mRNA, TSC2 protein expression, and the phosphorylation of the mammalian target of rapamycin (p-mTOR)/mTOR, we confirmed that the TSC2 KD microglia model was successfully established. Compared with the control group, the TSC2 KD group presented higher mRNA levels and fluorescence intensities of microglia AIF1 and CD68, as well as greater reactive oxygen species (ROS) production. Eight inflammasome-associated hub gene mRNA assays revealed that the expression of the NLRP3 and IL1B genes was increased. Compared with the control group, the TSC2 KD group presented increased levels of NLRP3 and Pro-IL-1β proteins in cells and Cleaved-Caspase 1 and Cleaved-IL-1β proteins in the supernatant, suggesting NLRP3 inflammasome activation. Rapamycin intervention alleviated these changes, demonstrating that the TSC2 gene regulation of microglial activation and NLRP3 inflammasome activation are correlated with mTOR phosphorylation. In conclusion, microglia are activated in TSC patients and participate in the NLRP3 inflammasome-associated neuroinflammatory response, and rapamycin treatment can alleviate these changes.
- 13 June 2025
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 131, 113-120
Expansion of the Epilepsy Genotype-Phenotype Spectrum: Genetic and Clinical Characterization of 288 Children with Epilepsy in China
- 13 June 2025
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 131, 113-120
Expansion of the Epilepsy Genotype-Phenotype Spectrum: Genetic and Clinical Characterization of 288 Children with Epilepsy in China
- Open Access
- 31 January 2025
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 20 (1) , 1-14
Heterozygous pathogenic STT3A variation leads to dominant congenital glycosylation disorders and functional validation in zebrafish
Background: Congenital disorders of glycosylation are a rare group of disorders characterized by impaired glycosylation, wherein STT3A encodes the catalytic subunit of the oligosaccharyltransferase complex, which is crucial for protein N-glycosylation. Previous studies have reported that STT3A-CDG is caused by autosomal recessive inheritance. However, in this study, we propose that STT3A-CDG can be pathogenic through autosomal dominant inheritance. Methods: The variant was identified via trio whole-exome sequencing. We constructed wild-type and variant plasmids, transfected them into HEK293T cells and detected the expression levels of the STT3A protein. We performed CRISPR-Cas9 to establish heterozygous knockdown zebrafish to validate the functional implications of autosomal dominant inheritance of STT3A in pathogenesis. Results: The patient presented with developmental delay, distinctive facial features, short stature, and abnormal discharges. The heterozygous pathogenic missense variant (NM_001278503.2: c.499G > T, NP_001265432.1:p. Asp167Tyr) was identified, and the Western blot results revealed a significant decrease in protein levels. Heterozygous knockdown zebrafish exhibit phenotypes similar to those of patients, including craniofacial dysmorphology (increased eye distance, increased Basihyal’s length, increased Ceratohyal’s angle), skeletal abnormalities (reduced number of mineralized bones), developmental delay (reduced adaptability under light‒dark stimuli suggesting abnormal locomotion, orientation, and social behavior), and electrophysiological abnormalities. Conclusion: We report a proband with a dominant congenital glycosylation disorder caused by heterozygous pathogenic STT3A variation, which is a new inheritance pattern of STT3A. Our report expands the known phenotype of dominant STT3A-CDGs. Furthermore, we provide in vivo validation through the establishment of a heterozygous knockdown zebrafish model for stt3a and strengthened the compelling evidence for dominant STT3A-related pathogenesis.
- 31 January 2025
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 20 (1) , 1-14
Open AccessHeterozygous pathogenic STT3A variation leads to dominant congenital glycosylation disorders and functional validation in zebrafish
Background: Congenital disorders of glycosylation are a rare group of disorders characterized by impaired glycosylation, wherein STT3A encodes the catalytic subunit of the oligosaccharyltransferase complex, which is crucial for protein N-glycosylation. Previous studies have reported that STT3A-CDG is caused by autosomal recessive inheritance. However, in this study, we propose that STT3A-CDG can be pathogenic through autosomal dominant inheritance. Methods: The variant was identified via trio whole-exome sequencing. We constructed wild-type and variant plasmids, transfected them into HEK293T cells and detected the expression levels of the STT3A protein. We performed CRISPR-Cas9 to establish heterozygous knockdown zebrafish to validate the functional implications of autosomal dominant inheritance of STT3A in pathogenesis. Results: The patient presented with developmental delay, distinctive facial features, short stature, and abnormal discharges. The heterozygous pathogenic missense variant (NM_001278503.2: c.499G > T, NP_001265432.1:p. Asp167Tyr) was identified, and the Western blot results revealed a significant decrease in protein levels. Heterozygous knockdown zebrafish exhibit phenotypes similar to those of patients, including craniofacial dysmorphology (increased eye distance, increased Basihyal’s length, increased Ceratohyal’s angle), skeletal abnormalities (reduced number of mineralized bones), developmental delay (reduced adaptability under light‒dark stimuli suggesting abnormal locomotion, orientation, and social behavior), and electrophysiological abnormalities. Conclusion: We report a proband with a dominant congenital glycosylation disorder caused by heterozygous pathogenic STT3A variation, which is a new inheritance pattern of STT3A. Our report expands the known phenotype of dominant STT3A-CDGs. Furthermore, we provide in vivo validation through the establishment of a heterozygous knockdown zebrafish model for stt3a and strengthened the compelling evidence for dominant STT3A-related pathogenesis.
- Open Access
- 22 January 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (2) , 269
Phagocytic Function Analyses of GABBR-Related Microglia in Immature Developing Epileptic Brain Based on 10× Single-Nucleus RNA Sequencing Technology
Background: Epilepsy is a neurological disorder defined by the occurrence of epileptic seizures, which can significantly affect children, often leading to learning and cognitive impairments. Microglia, the resident immune cells of the central nervous system, are essential in clearing damaged neurons through phagocytosis. Notably, GABBR-associated microglia have been implicated in regulating phagocytic activity. Since the phagocytic function of microglia is critical in the pathogenesis of epilepsy, this study aims to investigate the role of GABBR-associated microglia in the development of the immature brain following epileptic seizures. Methods: Epilepsy was induced in a mouse model by the intraperitoneal injection of KA. Changes in the expression of the GABBR-related gene, GABBR2, in hippocampal microglia were analyzed using single-nucleus RNA sequencing (snRNA-seq). Cognitive and emotional changes in the mice were assessed through behavioral analyses. The expression of GABBR2 was semi-quantitatively measured using Western blotting, quantitative reverse transcription PCR, and immunofluorescence. Additionally, the spatial relationship between GABBR2 and hippocampal neurons was evaluated using Imaris software. Results: The snRNA-seq analysis revealed that GABBR2 expression was elevated in activated microglia in the hippocampus during chronic epilepsy compared to the early phase of seizures. Behavioral assessments demonstrated heightened anxiety levels and learning and memory impairments in the chronic epilepsy group compared to the control group. GABBR2 expression was upregulated in chronic epilepsy. Three-dimensional reconstruction analyses revealed a significantly increased contact volume between GABBR-associated microglia and neurons in the chronic epilepsy group compared to the control group. Conclusions: GABBR-associated microglia significantly contribute to the progression of immature brain diseases by promoting neuronal phagocytic activity.
- 22 January 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (2) , 269
Open AccessPhagocytic Function Analyses of GABBR-Related Microglia in Immature Developing Epileptic Brain Based on 10× Single-Nucleus RNA Sequencing Technology
Background: Epilepsy is a neurological disorder defined by the occurrence of epileptic seizures, which can significantly affect children, often leading to learning and cognitive impairments. Microglia, the resident immune cells of the central nervous system, are essential in clearing damaged neurons through phagocytosis. Notably, GABBR-associated microglia have been implicated in regulating phagocytic activity. Since the phagocytic function of microglia is critical in the pathogenesis of epilepsy, this study aims to investigate the role of GABBR-associated microglia in the development of the immature brain following epileptic seizures. Methods: Epilepsy was induced in a mouse model by the intraperitoneal injection of KA. Changes in the expression of the GABBR-related gene, GABBR2, in hippocampal microglia were analyzed using single-nucleus RNA sequencing (snRNA-seq). Cognitive and emotional changes in the mice were assessed through behavioral analyses. The expression of GABBR2 was semi-quantitatively measured using Western blotting, quantitative reverse transcription PCR, and immunofluorescence. Additionally, the spatial relationship between GABBR2 and hippocampal neurons was evaluated using Imaris software. Results: The snRNA-seq analysis revealed that GABBR2 expression was elevated in activated microglia in the hippocampus during chronic epilepsy compared to the early phase of seizures. Behavioral assessments demonstrated heightened anxiety levels and learning and memory impairments in the chronic epilepsy group compared to the control group. GABBR2 expression was upregulated in chronic epilepsy. Three-dimensional reconstruction analyses revealed a significantly increased contact volume between GABBR-associated microglia and neurons in the chronic epilepsy group compared to the control group. Conclusions: GABBR-associated microglia significantly contribute to the progression of immature brain diseases by promoting neuronal phagocytic activity.
- 13 January 2025
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 297, 139841
Novel susceptibility genes for sleep apnea revealed by a cross-tissue transcriptome-wide association study
- 13 January 2025
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 297, 139841
Novel susceptibility genes for sleep apnea revealed by a cross-tissue transcriptome-wide association study